Quarterly ResultMay 8, 2026, 04:12 PM
Entera Bio Q1 Net Loss $3.5M; EB613 Phase 3 Protocol Submitted; $8.5M Investment
AI Summary
Entera Bio Ltd. reported a net loss of $3.5 million for the first quarter of 2026, an increase from $2.6 million in Q1 2025, with R&D expenses also rising. The company provided significant business updates, including the submission of a streamlined Phase 3 protocol for its oral osteoporosis treatment, EB613, to the FDA. Additionally, Entera expanded its 50/50 partnership with OPKO for EB612, an oral hypoparathyroidism treatment, with an IND filing expected in late 2026. A direct investment led by BVF Partners L.P. brought the company's cash and cash equivalents to $20.4 million as of May 8, 2026, expected to fund operations through Q1 2027.
Key Highlights
- Net loss for Q1 2026 was $3.5 million, compared to $2.6 million in Q1 2025.
- Research and development expenses increased to $2.3 million in Q1 2026 from $1.1 million in Q1 2025.
- Cash and cash equivalents were $11.9 million on March 31, 2026, rising to $20.4 million by May 8, 2026.
- EB613 Phase 3 protocol for oral osteoporosis treatment submitted to FDA, with feedback expected imminently.
- Expanded 50/50 partnership with OPKO for EB612 (oral hypoparathyroidism), targeting late 2026 IND filing.
- Direct investment led by BVF Partners L.P. provided $8.5 million to support EB613 study and working capital.
- Geno J. Germano appointed Chairman of the Board; Steve Rubin joined the Board of Directors.